title: Evaluation of the B-SAFE campaign to reduce clinically significant warfarin-drug interactions among fee-for-service Medicare beneficiaries.
abstract: The objective of this study was to evaluate the effectiveness of a health communication campaign designed to reduce the rate of serious warfarin-related drug interactions. The B-SAFE campaign was conducted in 2009 to educate patients located in a Michigan hospital's service area about the risk of serious adverse drug events associated with warfarin. The rate of warfarin-related drug interactions among Medicare fee-for-service (FFS) patients admitted to the exposed hospital with hemorrhagic complications was compared with the rate of warfarin-related drug interactions among a similar cohort admitted to a control hospital before and after the campaign. The χ(2) test and logistic regression were used to analyze differences. The authors observed a marginally significant decline in the rate of warfarin-related drug interactions (odds ratio [OR] = 0.66; 95% confidence interval [CI] = 0.33-1.29) among FFS Medicare patients admitted for bleeding complications to the hospital targeted by the B-SAFE campaign. The same association was not observed in the control hospital (OR = 1.15; CI = 0.42-3.14). These findings suggest that patient exposure to the B-SAFE campaign may have resulted in a decrease in the rate of clinically significant warfarin-related drug interactions.
authors.affiliation: St Joseph Mercy Health System, Ann Arbor, MI, USA. jmitchin@mpro.org
authors.forename: James C
authors.initials: JC
authors.lastname: Mitchiner
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Korzeniewski
authors.forename: David
authors.initials: D
authors.lastname: Betten
authors.forename: David
authors.initials: D
authors.lastname: Castle
authors.forename: Lakshmi
authors.initials: L
authors.lastname: Halasyamani
authors.forename: Susan M
authors.initials: SM
authors.lastname: Burns
authors.forename: Cherise
authors.initials: C
authors.lastname: Callahan
authors.forename: Christopher
authors.initials: C
authors.lastname: Manthey
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D004347:Drug Interactions; D018588:Fee-for-Service Plans; D005260:Female; D006293:Health Promotion; D006801:Humans; D008297:Male; D006278:Medicare; D010353:Patient Education as Topic / Q000379:methods*; D015397:Program Evaluation; D014481:United States; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000925:Anticoagulants; D014859:Warfarin